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The aim of this study was to evaluate the antidiabetic activity of LH II puriﬁed from ethanolic seed extract of Eugenia jambolana
in alloxan-induced mild diabetic (MD) and severely diabetic (SD) rabbits. Ethanolic extract upon chromatographic puriﬁcation
yielded partially puriﬁed hypoglycemic principle (SIII) which on further puriﬁcation by sephadex LH 20 yielded pharmacological
active compound LH II. Homogeneity of LH II was tested by HPLC. Phytochemical investigation of LH II by various structural
spectra showed the presence of saturated fatty acid, Δ5 lipid and presence of sterol. LH II was administered orally at a dose of
10mgkg−1 body weight to MD and SD. LH II resulted, signiﬁcant fall in FBG at 90min (21.2% MD: 28.6% SD), 7th day (35.6%
MD) and 15th day (59.6% SD). Glycosylated hemoglobin was signiﬁcantly decreased (50.5%) in SD after 15 days treatment (Tt).
Plasma insulinlevels were signiﬁcantly increased (P < .001). In vitro studies with pancreatic islets showed 3-fold increase in insulin
levels as compared to untreated animals. LH II also showed extrapancreatic eﬀect by signiﬁcantly increasing (P < .001) the activity
of key enzymes of glycolysis and signiﬁcantly decreasing (P < .001) the activity of key enzymes of gluconeogenesis. Liver and
muscle glycogen content were increased by 36.6 and 30% for MD, and 52 and 47% for SD, respectively. Thus, the present study
demonstrates that LH II possesses potent antidiabetic activity and it is eﬀective in both MD and SD rabbits.
1.Introduction
The world is facing an explosive increase in the incidence of
diabetes mellitus. According to the World Health Organiza-
tion (WHO) estimates, the number of adults with diabetes
in the world will rise from 135 million in 1995 to 300 million
in the year 2025 [1]. India is the diabetic capital of the world,
predictedtohave57.2milliondiabeticpopulationbytheyear
2025 [2].
A balance between glucose production and its utiliza-
tion is necessary to maintain normal blood glucose levels.
Diabetes is characterized by elevated production and low
utilization of glucose [3]. A number of changes in several
enzymes present in the liver and other tissues are known to
occur in diabetes mellitus, for example, activity of hepatic
glucokinase is markedly decreased and activity of glucose-
6-phosphatase is almost doubled [4]. This imbalance results
in constant hyperglycemia in the diabetic state. The chronic
hyperglycemia of diabetes is associated with long-term
dysfunction and damage to various organs. Hence, there is
a need to search for a medication for lowering glucose as
well as modify the alteration of key enzymes involved in
carbohydrate metabolism.
Despite the great strides that have been made in the
understanding and management of diabetes, the disease and
disease-related complications are increasing unabated [5].
Thoughdiﬀerenttypesoforalhypoglycemicagentsareavail-
able along with insulin for the treatment of diabetes mellitus,
healers heavily relied upon medicinal plants and herbs to
treat diabetes. Actually more than 1200 plants have been
described to be experimentally or ethnopharmacologically
used in the treatment of diabetes [6–15]. Based on the WHO
recommendations, hypoglycemic agents of plant origin are
important and warrant attention [16].2 Evidence-Based Complementary and Alternative Medicine
This article describes the study of active principle
puriﬁed from ethanolic seed extract of Eugenia jambolana
(Myrtaceae, common name: Black plum/Black berry in
English and Jamun/Jambul in Hindi). Eugenia jambolana
is a large tree found in all forests over the greater part of
India from the sub-Himalayan tract to extreme south. It
is also found in Thailand and Philippines. Fruits are oval
to elliptical 1.5–3.5cm long, dark purple or nearly black,
luscious, ﬂeshy and edible [17].
The antihyperglycemic activity of seeds of E. jambolana
is well documented [18–27]. Aqueous and ethanolic extracts
of seeds administered orally to experimental animals and
to human adults at various dose levels were found to be
active [20, 28]. Not only antihyperglycemic activity, but
hypolipidemic activity is also reported in our earlier studies
[23]. However, very few scientiﬁc studies are available about
puriﬁcation/isolation of active principle from ethanolic seed
extract of E. jambolana. In this article, we report the
puriﬁcation of active principle from ethanolic seed extract of
E. jambolana and study the eﬀect of puriﬁed active principle
on carbohydrate metabolism, in mild diabetic (MD) and
severely diabetic (SD), which is so far not reported in the
literature.
2. Methods
2.1. Plant Material. Fruits of E. jambolana were procured
from the Azadpur Mandi (vegetable market) at Delhi. The
identity was made with the help of a botanist using taxo-
nomic rules (voucher specimen no. P- 96/7) and specimen
are kept for further references in Botanical Garden, Kolkata,
India.
2.2. Animals. Male albino rabbits (1–1.5kg) were obtained
from Central Animal House, University College of Medical
Sciences (UCMS), Delhi, India. Rabbits were maintained on
a commercial diet (Hindustan Lever Ltd, Mumbai, India)
and water ad libitum. They were housed at a temperature
of 22 ± 2◦C with a schedule of 12h light and 12h dark
cycle. They were acclimatized to laboratory conditions at
least for 1 week before carrying out any experimental
work. The experimental protocol for the present study was
approved by Institutional Animal Ethical Committee (IAEC)
of University College of Medical Sciences, Delhi, India.
2.3. Induction of Experimental Diabetes. Experimental dia-
betes was induced in rabbits with alloxan (80mgkg−1
bodyweight, Sigma Chemicals, USA) dissolved in 0.1M
citrate buﬀer (pH 4.0), injected intravenously to overnight
fasted rabbits through their marginal ear vein [29]. The
animals were monitored for plasma glucose levels at weekly
intervals for a month. After one month, the rabbits showing
stabilized diabetes with fasting blood glucose (FBG) value
between 120 and 250mgdL−1 and having abnormal glucose
tolerance in glucose tolerance test (GTT) were considered
as MD and those with FBG value of 250mgdL−1 or above
as SD. Rabbits that did not show any increase in FBG levels
eveninitiallyafteralloxaninjectionwereconsideredastotally
resistant and excluded from studies.
2.4. Preparation of the Ethanolic Extract from Seeds of E.
jambolana Fruits. One kilogram fruits were ﬁrst purchased
from local market. Fruits were washed well with plenty of
tap water and pulp was separated manually from the seeds.
Seeds were washed thoroughly to remove all the traces of
pulp from the seeds. Seeds of E. jambolana were dried at
room temperature. Dried seeds were ground in an electric
grinder to obtain coarse seed powder. One hundred gram
seed powder was suspended in distilled water (250mL)
and allowed to stand at 4◦C. It was then ﬁltered through
several layers of muslin cloth and ﬁltrate (water extract)
was discarded. The residue was then extracted with ethanol
(80%) and allowed to stand for 48h at 4◦C. Finally, it was
extracted with 95% ethanol. The extract was ﬁltered through
seven to eight layers of muslin cloth and then lyophilized
at reduced pressure. The yield of alcoholic extract of E.
jambolana seeds was 1.5g 100g−1 of dried powdered seeds.
2.5. Puriﬁcation of Antihyperglycemic Component from
Ethanolic Extract of Seeds. The ethanolic extract showed
potent antihyperglycemic activity [23], it was subjected
to puriﬁcation via silica gel (60–120mesh) column chro-
matography. Fractions were eluted with 95% ethanol. Four
fractions were eluted. Out of four only one fraction (S III)
showed antihyperglycemic activity. Therefore, S III was fur-
ther puriﬁed via sephadex LH 20 column chromatography
(LH). It showed the presence of three fractions which were
designated as LH I, LH II and LH III. Activities of these three
were tested in alloxan-induced MD and SD rabbits. Dose of
the fractions was calculated by evaporating a known volume
to dryness.
2.6. Assessment of Antihyperglycemic Activity. Antihyper-
glycemic activity of LH I, LH II and LH III at a dose of
10mgkg−1 body weight were tested in both MD and SD
rabbits. The rabbits were divided into three groups (ﬁve
animals in each group). Group I served as healthy control.
Group II and III served as MD and SD, respectively. Both
Group II and III were further divided into diabetic control
rabbits (subgroup A), diabetic rabbits given LH I (subgroup
B), diabetic rabbits given LH II (subgroup C), diabetic
rabbits given LH III (subgroup D).
Antihyperglycemic activity was assessed by fall in FBG
after 90min of drug administration and reduction in blood
glucose tolerance test in MD rabbits and by fall in fasting
blood glucose only in SD rabbits (animals die if glucose
tolerance test is performed in severely diabetic rabbits).
LH II was found to possess potent anti hyperglycemic
activity (Table 1) and its homogeneity was tested via HPLC
employing GPC column (GPC, KF-803, 8 × 300mm 10 ×
length). LH II was eluted with 0.05M tris buﬀer, pH 7.2 and
monitored by UV detector at wavelength 254nm (Instru-
ment Waters HPLC model 510). Single peak was observed
at 22.11min after sample was injected, suggesting that LH II



























































































Figure 1: Antidiabetic eﬀect of LH II (10mgkg−1) in mild diabetic and severe diabetic rabbits. Values are mean ± SEM for ﬁve animals in
each group. ∗P<. 001 versus before treatment.
II via NMR, 2D COSY and HMQC showed the presence of
saturated fatty acid, Δ5 lipid and presence of sterol. Further
biochemical investigations to know the exact mechanism of
action were done with LHII (10mgkg−1 body weight (bw)).
The duration of treatment was 7 days for MD and 15 days for
SD rabbits.
2.7. Sample Collection. Fasting blood samples were taken
before and after treatment in both MD (7-day treatment)
and SD (15-day treatment) rabbits. Samples were withdrawn
from overnight fasted animals. Blood was collected in
tubes containing sodium ﬂuoride and potassium oxalate for
estimation of blood glucose. The whole blood, collected in
EDTA vials, was used to measure glycosylated hemoglobin
(GHb).
In order to know whether the LH II acts by stimulating
the release of insulin, plasma insulin was measured in MD
and SD rabbits. In vitro studies on the release of insulin
from the islets of Langerhans were also performed in
Table 1: Antihyperglycemic activity of LH I, LH II and LH III in









LH I 10 7 (↑)5 ( ↑)
LH II 10 21.2 (↓) 27.0 (↓)
LH III 10 10.0 (↓) No change
Severe Diabetic
LH I 10 9 (↑)—
LH II 10 28.6 (↓)—
LH III 10 12.0 (↓)—
diabetic rabbits. Insulin levels were estimated using enzyme-
linked immunosorbent assay kits (Boehringer Manheim,
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Figure 2: Eﬀect of LH II on Plasma insulin in mild diabetic and
severely diabetic rabbits. Values are mean ± S E Mf o rﬁ v ea n i m a l si n
each group. ∗P<. 001 versus before treatment.
At the end of the study, the rabbits were sacriﬁced, liver
and muscles tissues dissected for glycogen estimation. Activ-
itiesofkeyenzymesofcarbohydratemetabolism,thatis,glu-
cokinase, phosphofructokinase, glucose-6-phosphatase and
fructose-1,6-bisphosphatase were also measured in hepatic
tissues to know extrapancreatic eﬀect.
2.8. Biochemical and Enzymatic Estimations. Blood glucose
was estimated by glucose oxidase method [30]. HbA1c was
estimated by the method of Goldstein et al. [31]. Islets of
Langerhans were isolated as describe by our earlier studies
[32]. Plasma insulin was measured by the method of Burgi et
al. [33]. Key enzymes of glycolysis, that is, glucokinase [34],
phosphofructokinase [35] and of gluconeogenesis, that is,
glucose-6-phosphatase[36]andfructose-1,6-bisphosphatase
[37]wereestimatedbyalreadystandardizedprotocols.Tissue
glycogen was assayed as described by Carroll et al. [38].
2.9. Toxicity Studies. To evaluate the toxicity of high dose of
the LH II, three groups of fasted healthy rats (ﬁve animals
per group) were administered orally graded doses of LH
II (up to a dosage of 5, 10 and 15 times of the eﬀective
dose, that is, 10mgkg−1 bw) and one group was taken as
control given distilled water. The animals were observed
for 1h continuously and then hourly for 4h and ﬁnally
after every 24h up to 30 days for any gross behavioral
changes or mortality, if happens. Liver function tests such
as serum glutamate phosphotransferase (SGPT) and alkaline
phosphatase (ALP) as well as kidney function tests such as
urea and creatinine were performed in serum at the end of
the study using standard methods.
2.10. Statistical Analysis. Values were expressed as the mean
± SEM for ﬁve animals in each group. Statistical analysis
was done by using repeated measure analysis of variance
(ANOVA) and one-way ANOVA followed by Tukey’s multi-
ple comparison test at 5% level of signiﬁcance.
Table 2: Eﬀect of LH II on insulin release from isolated islets of
Langerhans of diabetic rabbits




Diabetic — 18195 ± 398.0 —
Diabetic + LH II 10mgkg−1 56250 ± 153.6∗ 3-fold




LH II (at a dose of 10mgkg−1 bw) was found to be more
potent in reducing fasting blood glucose (21.2%) within
90min and improving peak blood glucose (27% fall) during
glucose tolerance test in mild diabetic rabbits. However
there was 28.6% fall in FBG of SD rabbits. Hence, further
biochemical studies were carried out with LH II only at
ad o s eo f1 0m gk g −1.
3.2. FBG, OGTT and GHb. As shown in Figure 1,L HI I
resulted 35.6% fall in FBG and 51.3% fall in peak blood
g l u c o s ed u r i n gG T Ti nM Da f t e r7d a y st r e a t m e n ta n di nS D
rabbits, 59.6% fall in FBG and 50.5% fall in HbA1c after 15
days treatment.
3.3. Insulin Levels: Both In Vivo and In Vitro. Oral admin-
istration of LH II, resulted signiﬁcant increase in plasma
insulin levels, that is, 38.4% in MD and 44.0% in SD
(Figure 2). In vitro studies conducted in diabetic rabbits
resulted in 3-fold increase of insulin release (Table 2).
3.4. Hepatic Enzymes. Figure 3 shows glucokinase, phos-
phofructokinase, glucose-6-phosphatase and fructose-1,6-
bis phosphatase activities in the livers of control and diabetic
rabbits.
In diabetic rabbits, activities of key enzymes of glycolysis
decrease and key enzymes of gluconeogenesis increase. After
oral administration of LH II, these activities were partially
restored to near normal levels in both MD and SD rabbits.
3.5. Total Lipids and Glycogen Content. Figure 4 shows, the
levels of total lipids in liver and glycogen in both liver and
muscle.Aincreaseintotallipidswasfoundindiabeticrabbits
when compared with control. The administration of LH II
(10mgkg−1) resulted in signiﬁcant reduction in total lipids
in both MD (10.7% fall) and SD (11.5%) and signiﬁcant
increase in liver and muscle glycogen content (P < .001) in
both MD and SD rabbits.
3.6. Toxicity Studies. Toxicity studies revealed that the
administration of graded doses of LH II (up to a dosage
of 5, 10 and 15 times of 10mgkg−1)p r o d u c e dn oa d v e r s e
eﬀect on the general behavior or appearance of the animals
and all the rats survived during the whole experimental
period. No signiﬁcant change was observed in the levels of










































































































































































































































Figure 3: Eﬀect of LH II on carbohydrate metabolizing enzymes in mild diabetic and severely diabetic rabbits. Values are mean ± SEM for
ﬁve animals in each group. ∗P<. 001, ∗∗P<. 001, ∗∗∗P<. 005 versus before treatment.
control group. The levels of urea and creatinine were also not
signiﬁcantly changed in treated animals compared to control
(Table 3).
4. Discussion
Hypoglycemic and hypolipidemic eﬀect of ethanolic extract
of seeds of E. jambolana in normal and alloxan induced
(80mgkg−1) MD and SD rabbits had already been shown
[23]. The main goal of present study was to purify active
principle from ethanolic seed extract and ﬁnd its exact
mechanism of action in respect of carbohydrate metabolism.
Studies conducted by us using graded doses of LH II
for various periods revealed the non-toxic nature of the LH
II. Rabbits that were administered LH II did not show any
drug induced toxic symptoms, even after 4 weeks of the
experimental period. Thus, the LH II was found to be safe
for further biological studies.
As shown in Table 1, LH II showed signiﬁcant anti-
hyperglycemic activity (P<. 001). MD and SD failed to
achieve euglycemia but caused a signiﬁcant (P<. 001)
reduction in glucose levels compared to their initials values.
Although, the percent fall in blood glucose was found to be
signiﬁcant in MD rabbits which had functional pancreatic
β-cells, signiﬁcant fall in SD rabbits suggested that the LH
II did not necessarily require the presence of functional
pancreatic β-cells for its favorable action. It means that it
could act in a variety of diabetic conditions with or without
functioning pancreatic β-cells. During diabetes, the excess of
glucose present in the blood reacts with Hb to form GHb.
Therateofglycosylationisproportionaltotheconcentration
of blood sugar at the peak of the glucose tolerance curve,
correlates with glycosylation [39] and, with an improvement
in glycemic control, GHb also decrease. Hence, estimation
of glycosylation of Hb is a well-accepted parameter used in
the management and prognosis of the disease [40]. In the
presentstudy,administrationoftheLHIItendedtobringthe
altered level of GHb toward normal range in both MD and
SD rabbits. This was due to the improved glycemic control
produced by the LH II.
The loss of body weight is one of the threats associated
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Figure 4: Eﬀect of LH II on total lipids and glycogen content in mild diabetic and severely diabetic rabbits. Values are mean ± SEM for ﬁve
animals in each group. ∗P<. 001, ∗∗P<. 001 versus before treatment.
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Figure 5: Therapeutic approach of active principle (LH II) puriﬁed from seeds of Eugenia jambolana on altered carbohydrate metabolism.Evidence-Based Complementary and Alternative Medicine 7
Table 3: Eﬀect on liver and kidney function tests during oral toxicity studies of active principle (LH II) isolated from ethanolic extract of
seeds in normal rabbits (1 month treatment).
Parameter Healthy control Treated 5 times of
eﬀective dose
Treated 10 times of
eﬀective dose
Treated 15 times of
eﬀective dose
Serum Bilirubin (mgdL−1) 0.45 ± 0.02 0.44 ± 0.03 0.44 ± 0.02 0.44 ± 0.02
SGPT (IUL−1) 11.2 ± 1.1 12.1 ± 1.3 11.5 ± 0.9 11.5 ± 0.9
Serum ALP (UL−1) 33.0 ± 2.4 33.2 ± 3.1 33.0 ± 2.8 33.0 ± 2.8
Serum protein (gdL−1) 8.0 ± 0.9 7.9 ± 0.6 8.0 ± 0.6 8.0 ± 0.2
Blood urea (mgdL−1) 15.0 ± 1.3 15.0 ± 1.7 15.9 ± 1.5 15.4 ± 1.8
Serum Creatinine (mgdL−1) 1.3 ± 0.1 1.4 ± 0.3 1.4 ± 0.1 1.4 ± 0.2
Values are mean ± SEM for ﬁve animals in each group. No signiﬁcant diﬀerence between control and treated groups.
thislossandratherresultedinincreaseofbodyweightinMD
and SD rabbits.
Antihyperglycemic action of LH II may be due to
increased utilization of glucose in the liver by glycogen
synthesis, decreased degradation of glycogen to give blood
sugar and also to decrease gluconeogenesis [41]. Another
possible mechanism of lowering blood glucose levels may be
by potentiation of the insulin eﬀect by increasing either the
pancreatic secretion of insulin from β-cells of the islets of
Langerhan’s or the responsiveness to insulin.
Diabetes mellitus cause a disturbance in the uptake of
glucose, as well as glucose metabolism. The liver plays an
important role in the maintenance of blood glucose levels
by regulating its metabolism. The activity of glucokinase,
which brings about the ﬁrst phosphorylation step of glu-
cose metabolism and phosphofrutokinase was signiﬁcantly
reduced in diabetic rabbits. This could be the reason for
the diminished utilization of glucose in the system and the
increased amount of glucose in the blood [42]. Increased
glucokinase activity was observed in the alloxan induced
diabetic rabbits treated with LH II, which would have
resulted in the activation of glycolysis, which, in turn,
increased the utilization of glucose by restoring insulin
secretion in the treated rabbits.
Glucose-6-phosphatase is one of the important regula-
tory enzyme of the gluconeogenic pathway [43]. Fructose-
1,6-bisphosphatase is the key enzyme catalyzing the rate
limiting steps of fructose-1,6-bisphosphate to fructose-6-
phosphate. The activities of glucose-6-phosphatase and
fructose-1,6-bisphosphatase are increased in the liver in
diabetic subject [44]. This results in a decrease in the
glycolytic ﬂux. Under normal condition, insulin functions as
a suppressor of gluconeogenic enzymes [45]. The increased
activities of these gluconeogenic enzymes in diabetic rabbits
were restored to near normal levels, after administration of
LH II. The possible mechanism by which LH II brought
about the normalization of enzymes might be by potentia-
tion of insulin release from β-cells of the islets of Langerhan’s
or its release from the bound form.
Glycogen is the primary intracellular storage form of
glucose and its levels in various tissues are a direct reﬂec-
tion of insulin activity, because insulin promotes glycogen
deposition by stimulating glycogen synthase and inhibiting
glycogen phosphorylase [46]. Diabetes mellitus is associated
with a marked decrease in the level of liver glycogen [47,
48]. Our data also showed signiﬁcant decrease in hepatic
and skeletal glycogen content in diabetic control. Oral
administration of LH II to diabetic rabbits showed an
increaseinglycogencontentofliverandskeletalmuscles;this
might be due to decreased glycogen phosphorylase activity
and increased glycogen synthase activity.
Our ﬁndings suggested that LH II could prove to be
an excellent agent in the control of experimental diabetes.
Therefore, the mechanism of action of LH II appeared to be
both pancreatic [19] and extra-pancreatic as E. jambolana is
reportedtoinhibitinsulinaseactivityinbothliverandkidney
[20]. The results of present study provides impetus for
furthermolecularandmechanisticstudiesonthetherapeutic
action of LH II, before it can be administered as possible
insulin replacement or adjuvant in the management of
diabetes mellitus.
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